SB 201146

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526252

CAS#: 141311-11-7

Description: SB 201146 is a leukotriene B4 antagonist. SB 201146 is a trisubstituted pyridine with high affinity for the LTB4 receptor.

Chemical Structure

img
SB 201146
CAS# 141311-11-7
Instruction

Theoretical Analysis

MedKoo Cat#: 526252
Name: SB 201146
CAS#: 141311-11-7
Chemical Formula: C30H35LiN2O5S
Exact Mass: 542.24
Molecular Weight: 542.620
Elemental Analysis: C, 66.41; H, 6.50; Li, 1.28; N, 5.16; O, 14.74; S, 5.91

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SB 201146; SB201146; SB-201146.

IUPAC/Chemical Name: 3-(6-(((3-Aminophenyl)sulfinyl)methyl)-3-((8-(4-methoxyphenyl)octyl)oxy)pyridin-2-yl)acrylic acid lithium salt

InChi Key: RVRATNAADXHAQO-ZJSKVYKZSA-M

InChi Code: InChI=1S/C30H36N2O5S.Li/c1-36-26-15-12-23(13-16-26)9-6-4-2-3-5-7-20-37-29-18-14-25(32-28(29)17-19-30(33)34)22-38(35)27-11-8-10-24(31)21-27;/h8,10-19,21H,2-7,9,20,22,31H2,1H3,(H,33,34);/q;+1/p-1/b19-17+;

SMILES Code: O=C([O-])/C=C/C1=NC(CS(C2=CC=CC(N)=C2)=O)=CC=C1OCCCCCCCCC3=CC=C(OC)C=C3.[Li+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 542.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 2003 Apr;123(4):1240-7. PubMed PMID: 12684317.

2: Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med. 2000 Jun;161(6):1881-6. PubMed PMID: 10852761.

3: Lee E, Lindo T, Jackson N, Meng-Choong L, Reynolds P, Hill A, Haswell M, Jackson S, Kilfeather S. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med. 1999 Dec;160(6):2079-85. PubMed PMID: 10588632.

4: Salmon M, Walsh DA, Huang TJ, Barnes PJ, Leonard TB, Hay DW, Chung KF. Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats. Br J Pharmacol. 1999 Jul;127(5):1151-8. PubMed PMID: 10455261; PubMed Central PMCID: PMC1566132.

5: Daines RA, Chambers PA, Foley JJ, Griswold DE, Kingsbury WD, Martin LD, Schmidt DB, Sham KK, Sarau HM. (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity. J Med Chem. 1996 Sep 13;39(19):3837-41. PubMed PMID: 8809171.

6: Daines RA, Chambers PA, Pendrak I, Jakas DR, Sarau HM, Foley JJ, Schmidt DB, Kingsbury WD. Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships. J Med Chem. 1993 Oct 29;36(22):3321-32. PubMed PMID: 8230122.